Dawson, TM, Dawson, VL.
Molecular pathways of neurodegeneration in Parkinson’s disease. Science.
McNaught, KS, Olanow, CW.
Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol.
Moore, DJ, West, AB, Dawson, VL, Dawson, TM.
Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci.
Polymeropoulos, MH, Lavedan, C, Leroy, E, Ide, SE, Dehejia, A, Dutra, A, et al.
Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science.
Kitada, T, Asakawa, S, Hattori, N, Matsumine, H, Yamamura, Y, Minoshima, S, et al.
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature.
Leroy, E, Boyer, R, Auburger, G, Leube, B, Ulm, G, Mezey, E, et al.
The ubiquitin pathway in Parkinson’s disease. Nature.
Bonifati, V, Rizzu, P, van Baren, MJ, Schaap, O, Breedveld, GJ, Krieger, E, et al.
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science.
McNaught, KS, Jenner, P.
Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett.
McNaught, KS, Belizaire, R, Jenner, P, Olanow, CW, Isacson, O.
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett.
McNaught, KS, Belizaire, R, Isacson, O, Jenner, P, Olanow, CW.
Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol.
Fornai, F, Lenzi, P, Gesi, M, Ferrucci, M, Lazzeri, G, Busceti, CL, et al.
Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci.
McNaught, KS, Perl, DP, Brownell, AL, Olanow, CW.
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol.
Schapira, AH, Cleeter, MW, Muddle, JR, Workman, JM, Cooper, JM, King, RH.
Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol.
Mathur, BN, Neely, MD, Dyllick-Brenzinger, M, Tandon, A, Deutch, AY.
Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res.
Landau, AM, Kouassi, E, Siegrist-Johnstone, R, Desbarats, J.
Proteasome inhibitor model of Parkinson’s disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov Disord.
Kordower, JH, Kanaan, NM, Chu, Y, Suresh Babu, R, Stansell, J 3rd, Terpstra, BT, et al.
Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys. Ann Neurol.
Manning-Boğ, AB, Reaney, SH, Chou, VP, Johnston, LC, McCormack, AL, Johnston, J, et al.
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol.
Hawlitschka, A, Haas, SJ, Schmitt, O, Weiss, DG, Wree, A.
Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res.
Braak, H, Del Tredici, K, Rub, U, de Vos, RA, Jansen Steur, EN, Braak, E.
Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging.
Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord.
Zarow, C, Lyness, SA, Mortimer, JA, Chui, HC.
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol.
Rideout, HJ, Lang-Rollin, IC, Savalle, M, Stefanis, L.
Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem.
Suh, J, Lee, YA, Gwag, BJ.
Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures. J Neurochem.
Lang-Rollin, I, Vekrellis, K, Wang, Q, Rideout, HJ, Stefanis, L.
Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem.
Qiu, JH, Asai, A, Chi, S, Saito, N, Hamada, H, Kirino, T.
Proteasome inhibitors induce cytochrome c-caspase-3-like proteasemediated apoptosis in cultured cortical neurons. J Neurosci.
Sullivan, PG, Dragicevic, NB, Deng, JH, Bai, Y, Dimayuga, E, Ding, Q, et al.
Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem.
Wagenknecht, B, Hermisson, M, Groskurth, P, Liston, P, Krammer, PH, Weller, M.
Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem.
Goldbaum, O, Vollmer, G, Richter-Landsberg, C.
Proteasome inhibition by MG-132 induces apoptotic cell death and mitochondrial dysfunction in cultured rat brain oligodendrocytes but not in astrocytes. Glia.
Hypothesis: proteasomal dysfunction: a primary event in neurodegeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann N Y Acad Sci.
Kikuchi, S, Shinpo, K, Tsuji, S, Takeuchi, M, Yamagishi, S, Makita, Z, et al.
Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res.
Mytilineou, C, McNaught, KS, Shashidharan, P, Yabut, J, Baptiste, RJ, Parnandi, A, et al.
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm.
Lev, N, Melamed, E, Offen, D.
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett.
Yamamoto, N, Sawada, H, Izumi, Y, Kume, T, Katsuki, H, Shimohama, S, et al.
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem.
Hung, CC, Davison, EJ, Robinson, PA, Ardley, HC.
The aggravating role of the ubiquitin-proteasome system in neurodegenerative disease. Biochem Soc Trans.
Ardley, HC, Hung, CC, Robinson, PA.
The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett.
Shimura, H, Hattori, N, Kubo, S, Yoshikawa, M, Kitada, T, Matsumine, H, et al.
Immumohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol.
Schlossmacher, MG, Frosch, MP, Gai, WP, Medina, M, Sharma, N, Forno, L, et al.
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol.
Rideout, HJ, Wang, Q, Park, DS, Stefanis, L.
Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci.
Dietrich, P, Rideout, HJ, Wang, Q, Stefanis, L.
Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. Mol Cell Neurosci.